OncoMatch/Clinical Trials/NCT07210086
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
Is NCT07210086 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ADT and ARSI for prostate cancer.
Treatment: ADT · ARSI — This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT). Specifically, it investigates how often early progression is detected on PSMA-PET before PSA rise, examines PET responses of lesions treated with RT at 6 and 12 months and their correlation with PSA changes and later progression, examines ctDNA changes following ablative-intent RT to metastatic sites, and explores the relationship between PSMA-PET radiological findings and ctDNA dynamics.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
KPS OR ECOG 0–1
KPS ≥ 70 or ECOG 0-1
Prior therapy
Cannot have received: androgen deprivation therapy
Exception: ≤ 3 months of neoadjuvant ADT prior to consent allowed
Any patient planning to receive lifelong continuous or intermittent ADT; For the current treatment course, patient must not have received more than 3 months of neoadjuvant ADT prior to consent.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify